Sally Susman - 23 Feb 2024 Form 4 Insider Report for PFIZER INC (PFE)

Role
Executive Vice President
Signature
Susan E. Grant, by power of atty., for Sally Susman
Issuer symbol
PFE
Transactions as of
23 Feb 2024
Net transactions value
+$195,956
Form type
4
Filing time
27 Feb 2024, 13:46:47 UTC
Previous filing
28 Feb 2023
Next filing
28 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PFE Common Stock Options Exercise $1,745,304 +63,837 +41% $27.34 218,148 23 Feb 2024 Direct F1
transaction PFE Common Stock Tax liability $137,356 -4,948 -2.3% $27.76 213,200 23 Feb 2024 Direct F2
transaction PFE Common Stock Tax liability $1,411,991 -51,589 -24% $27.37 161,611 23 Feb 2024 Direct F3, F4
holding PFE Common Stock 813 23 Feb 2024 By Rule 16b-3 Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PFE Stock Appreciation Rights Options Exercise $0 -63,837 -100% $0.000000* 0 23 Feb 2024 Common Stock 63,837 $27.34 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2 The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3 The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F4 Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.